Case Reports in Hematology / 2016 / Article / Tab 1

Case Report

A Case of Chyloperitoneum Secondary to Follicular Lymphoma and a Review of Prognostic Implications

Table 1

Chyloperitoneum associated with lymphoma.

Case numberAuthor/yearAge/sexSiteDiagnosisTreatmentOutcome

1Current case78/FPeritoneal,
pleural,
Follicular lymphomaBendamustine + rituximabResolution
2Arasawa, 2014 [3]74/MPeritonealDLBCLR-CHOPResolution
3Jiang, 2013 [4]28/MPeritoneal,
pleural
Non-Hodgkin LymphomaDOLP +
HDAra-C
Resolution
4Yamamoto, 2013 [5]87/MPeritonealDLBCLR-CHOPResolution
5Etonyeaku, 2012 [6]18/FPeritoneal,
pleural
Burkitt’s lymphomaMEVDied due to treatment effects
6Kashyap, 2011 [7]21/FPeritoneal,
pleural,
pericardial
DLBCLR-CHOPResolution
7Ionnidou-Papagiannaki 2009 [8]38/MPeritoneal,
pleural,
pericardial
T-cell lymphomaCHOEPDied due to GI bleeding
8Gonen, 2007 [9]53/MPeritonealHodgkin lymphomaABVDRegression after two cycles chemotherapy
9Ward, 2008 [10]Middle age/FPeritonealFollicular lymphomaChemotherapy unspecifiedResolution
10Bachmeyer, 2004 [11]71/MPeritonealFollicular
lymphoma
CHVP + interferon alpha50% reduction
11Oosterbosch, 1995 [12]68/FPeritoneal,
pleural
DLBCLCVPRegression
12Hufford, 1988 [13]49/FPeritonealMixed cellularity (Hodgkin lymphoma)CVP, doxorubicin
followed by CHOP
Resolution
13Hufford. 1988 [13]67/FPeritonealSmall cleaved cell (NHL)CVPNo response to chemotherapy, resolution after diuretics
14Hufford, 1988 [13]58/MPeritonealHodgkin lymphomaMOPPResolution
15Hufford, 1988 [13]60/MPeritonealSmall cleaved cell (NHL)CHOMP + bleomycinResolution

R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisolone; CHOMP: cyclophosphamide, doxorubicin, vincristine, and prednisone + bleomycin; MOPP: Mustargen, Oncovin, procarbazine, and prednisone; CHVP: cyclophosphamide, doxorubicin, etoposide, and prednisolone; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; CHOEP: cyclophosphamide, hydroxydaunorubicin, Oncovin, etoposide, and prednisone; DOLP: daunorubicin, vincristine, L-asparaginase, and prednisone; HDAra-C: high dose cytarabine; MEV: methotrexate, cyclophosphamide, and vincristine.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.